Clinical trials: Everolimus
Kidney Transplant Failure and Rejection
Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection
Background: Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system…
- Trial name
- STARR (NCT03955172)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Aging, Insulin Resistance
Everolimus Aging Study
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans.
- Trial name
- EVERLAST (NCT05835999)
- Testing
- Everolimus 0.5 MG once per day, Everolimus 5 MG once per week
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Aging
MTOR Inhibitors in Older Adults
Over the past decades, healthcare systems face significant challenges to meet the needs of an aging population due to progressive debility, functional decline and chronic diseases development.
- Trial name
- NCT06727305
- Testing
- Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Aging
RESTOR: PK/PD mTORi Inhibition in Older Adults
As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease.
- Trial name
- RESTOR (NCT06658093)
- Testing
- Rapamycin, Everolimus
- Where
- United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Aging
Rapalog Pharmacology (RAP PAC) Study
The objective of RAP PAC is to identify safe and effective weekly dose(s) for the mTOR inhibitors sirolimus and everolimus that intervene on the underlying fundamental biology of aging.
- Trial name
- NCT05949658
- Testing
- Sirolimus, Everolimus
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Postmenopausal Women
Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women
It is estimated that women lose around 20-25% of bone mass during the 5-10 years period of postmenopausal transition, and menopause is considered a major risk factor for osteoporotic fragility fracture.
- Trial name
- RapaLoad (NCT06789900)
- Testing
- Everolimus (Afinitor®), Football Fitness Concept
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Healthy, Osteopenia
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women
The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in elderly women aged 60-75 years.
- Conditions
- Healthy, Osteopenia, Osteoporosis Risk
- Trial name
- StrongBone (NCT07191353)
- Testing
- Everolimus, Resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Pharmacokinetics
Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults
The purpose of this study is to determine the pharmacokinetics and safety of SVG101 (dispersible tab. of everolimus) in healthy volunteers compared to Afinitor tab. after oral administration.
- Trial name
- NCT05490095
- Testing
- SVG101 (T), Afinitor (R)
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sovargen
Hepatic Insufficiency
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
- Trial name
- NCT00968591
- Testing
- Everolimus
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Glioma
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1). Additionally, the safety of RAD001 will be studied.
- Trial name
- NFC-RAD001 (NCT01158651)
- Testing
- RAD001 (Everolimus)
- Where
- 12 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Fallopian Tube Cancer, Peritoneal Cavity Cancer
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT01281514
- Testing
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Respiratory Tract Infections
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in…
- Trial name
- NCT03373903
- Testing
- BEZ235, BEZ235 plus everolimus (RAD001)
- Where
- United States
- Volunteers
- 652 people, healthy volunteers welcome
- Sponsor
- Restorbio Inc.
Neoplasm
Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls
The purpose of this research study is to understand if platelets in the blood become more active during cancer and specially advanced stages of cancer, in the future the investigators want to see if reducing platelet activity can…
- Trial name
- NCT02450175
- Testing
- Everolimus, Letrozole
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinai Hospital of Baltimore
Disorder Related to Renal Transplantation
Efficacy of Certican® in Combination With Myfortic® in Renal
The primary objective is to demonstrate the superiority of everolimus plus Myfortic® plus corticosteroids following CNI withdrawal at week 16 compared to tacrolimus plus Myfortic® plus corticosteroids as measured by the change in…
- Trial name
- HUSJ1 (NCT01399242)
- Testing
- Certican
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Universitário São José